The estimated Net Worth of Brigit Riley is at least $1.66 Milion dollars as of 15 March 2023. Dr Riley owns over 7,299 units of Adverum Biotechnologies Inc stock worth over $825,568 and over the last 3 years he sold ADVM stock worth over $13,468. In addition, he makes $816,075 as Chief Scientific Officer at Adverum Biotechnologies Inc.
Dr has made over 2 trades of the Adverum Biotechnologies Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 7,299 units of ADVM stock worth $5,693 on 15 March 2023.
The largest trade he's ever made was selling 7,299 units of Adverum Biotechnologies Inc stock on 15 March 2023 worth over $5,693. On average, Dr trades about 2,913 units every 35 days since 2022. As of 15 March 2023 he still owns at least 117,435 units of Adverum Biotechnologies Inc stock.
You can see the complete history of Dr Riley stock trades at the bottom of the page.
Dr. Brigit Riley Ph.D. is the Chief Scientific Officer at Adverum Biotechnologies Inc.
As the Chief Scientific Officer of Adverum Biotechnologies Inc, the total compensation of Dr D at Adverum Biotechnologies Inc is $816,075. There are 4 executives at Adverum Biotechnologies Inc getting paid more, with Leone Patterson having the highest compensation of $2,830,320.
Dr D is 43, he's been the Chief Scientific Officer of Adverum Biotechnologies Inc since . There are 16 older and 2 younger executives at Adverum Biotechnologies Inc. The oldest executive at Adverum Biotechnologies Inc is Richard Spivey, 69, who is the Independent Director.
Brigit's mailing address filed with the SEC is C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY, CA, 94063.
Over the last 9 years, insiders at Adverum Biotechnologies Inc have traded over $1,591,374 worth of Adverum Biotechnologies Inc stock and bought 912,973 units worth $4,153,055 . The most active insiders traders include Patrick Machado, Braden Michael Leonard a Thomas Woiwode. On average, Adverum Biotechnologies Inc executives and independent directors trade stock every 40 days with the average trade being worth of $200,186. The most recent stock trade was executed by Braden Michael Leonard on 30 July 2024, trading 85,800 units of ADVM stock currently worth $613,470.
adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
Adverum Biotechnologies Inc executives and other stock owners filed with the SEC include: